Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) has been published in the British Journal of Haematology. The publication represents a major milestone for the CTN by marking the completion of its first trial. MUK one, a Phase II multicentre, open label, randomised trial aimed to identify the optimal starting dose of bendamustine when given in combination with thalidomide and dexamethasone in relapsed and/or refractory myeloma patients. The results demonstrated that a dose of 60mg/m2 given twice a month with thalidomide and dexamethasone was tolerable over repeated cycles and showed substantial clinical activity in heavily pretreated patients. This combination therefore provides an possible alternative treatment option for myeloma patients who have already received several lines of treatment.
